Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 163Carcinoma, Renal Cell 45Urinary Bladder Neoplasms 33Carcinoma, Transitional Cell 19Lung Neoplasms 14Melanoma 11Neoplasm Metastasis 10Glioma 10Breast Neoplasms 9Wilms Tumor 8Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Sarcoma 7Kidney Neoplasms 7Colorectal Neoplasms 7Uterine Cervical Neoplasms 6Ureteral Neoplasms 6Testicular Neoplasms 6Rhabdoid Tumor 6Pancreatic Neoplasms 6Neuroectodermal Tumors, Primitive, Peripheral 6Neuroblastoma 6Medulloblastoma 6Lymphoma, Non-Hodgkin 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Hepatocellular 6Brain Neoplasms 6

Interventions

fluciclovine F-18 2relatlimab 1pembrolizumab 1enfortumab vedotin 1darolutamide 1Radiation Dose Hypofractionation 1Nivolumab 1Mitomycin 1Magnetic Resonance Spectroscopy 1Gemcitabine 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Diseases × Magnetic Resonance Spectroscopy × Genitourinary × Clear all
NCT02830880 2020-01-07

FACBC Prostate Therapy Response

Emory University

Phase 2 Completed
7 enrolled 10 charts
Genitourinary

Urogenital Diseases, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡